Clinical Trials Logo

Parapneumonic Effusion clinical trials

View clinical trials related to Parapneumonic Effusion.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03873766 Completed - Empyema, Pleural Clinical Trials

Management of Pleural Space Infections

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

Currently, there is no high-quality evidence comparing the clinical outcomes and cost effectiveness of surgical drainage combined with antibiotics versus dual-agent intrapleural fibrinolytic therapy (IPFT) catheter drainage of pleural space infections with concomitant antibiotic therapy. The absence of comparative data is a challenge for surgical and medical services in clinical decision-making for this common and morbid condition. This is a pilot study comparing surgical drainage of the pleural space in complex pleural effusions to bedside chest tube drainage using dual agent IPFT with the intent to inform on study algorithm and endpoint performance in anticipation of a multi-institutional randomized clinical trial.

NCT ID: NCT03583931 Completed - Coagulopathy Clinical Trials

Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication

Start date: July 26, 2018
Phase: N/A
Study type: Interventional

This study aims to standardize the treatment of pleural space (parapneumonic) infections by comparing the difference in outcomes between 2 methods of treatment: early VATS (Video Assisted Thorascopic Surgery) decortication versus fibrinolytic therapy. During treatment, the patient's coagulopathy status will also be evaluated.

NCT ID: NCT03468933 Completed - Pleural Diseases Clinical Trials

Fibrinolysis Compared to Thoracoscopy for Pleural Infection

Start date: November 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this prospective randomized clinical trial is to compare two currently accepted standard-of-care treatment strategies: Medical thoracoscopy as compared to instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic effusion (CPPE) in adults.